CN
时迈药业
2016
时迈药业
2017
时迈药业
2018
时迈药业
2019
时迈药业
2020
时迈药业
2021
时迈药业
2022
时迈药业
2023
时迈药业
2024
时迈药业
2025
2016
Mar: CentryMed Pharmaceutical Inc. established in Maryland, USA.
2017
Sep: Zhejiang CentryMed Pharmaceutical Co., Ltd. founded in Hangzhou, China.
2018
Aug: Completed Series A financing.
Nov: Selected as a Hangzhou Tech-based Startup.
Dec: Awarded for Entrepreneurship & Innovation by High-level Overseas Returnee Team.
2019
Dec: Recognized under the “5050 Plan” and Zhejiang Overseas High-level Talent Program.
2020
Apr: Named Hangzhou Leading Entrepreneurial Team (2019).
Jul: Selected as a Zhejiang Tech-based SME.
Aug: Completed Series B financing.
Aug: IND approval from NMPA for Class I new drug DNV3.
Oct: 1st Prize, Zhejiang Final of China Innovation & Entrepreneurship Competition.
Nov: Became a governing unit of Biopharma Innovation Alliance (Binjiang).
2021
Apr: Named “Hangzhou Quasi-Unicorn Enterprise 2021”.
Aug: IND approvals from NMPA for bispecific SMET12 and CMD003.
Aug: Approved to establish Municipal High-tech R&D Center for Antibody Innovation.
Sep: 1st Prize, “Maker in China” Zhejiang Final.
Oct: Selected for Zhejiang “Leading Goose” R&D Program (2022).
Nov: • 2nd Prize, “Maker in China” National Final; IND approval for SMET12 from FDA.
2022
Jan: Completed Series C financing.
May: Granted Shandong Major Antibody Innovation Project.
Jun: IND approval for DNV3 + PD-1 combo; Named KPMG China Biotech 50.
Aug: Honored as Key Biopharma Enterprise in Hangzhou.
Nov–Dec: Recognitions include Expert Workstation, Industry-University Base, and National Disruptive Technology Award.
2023
Jan: Named Zhejiang “Specialized & Innovative” SME.
Mar: IND approval for SMET12 + Toripalimab (NMPA).
Apr: Recognized again as Hangzhou Quasi-Unicorn.
Aug: 3rd Prize, HICOOL Global Entrepreneurship Competition.
Oct: Received dual grants for preclinical and new drug R&D.
Oct: IND approval for CMD011 (NMPA); Listed as Pre-IPO Key Enterprise.
Nov–Dec: Selected as Zhejiang Top 50 Most Investable Company and Leading Goose R&D Program (2024).
2024
Jan: Recognized as Zhejiang Leading Innovation Team (2024).
Apr: Again named Hangzhou Quasi-Unicorn.
Sep–Oct: IND approvals from NMPA for CMDE005 and DNV3 combo therapy.
Nov: Selected for “Pioneer & Goose + X” Science and Technology Program (2025).
2025
Jan: Selected as “Top 10 Emerging Enterprises in Binjiang Innovation Zone”.
Feb: IND approval from FDA for CMD011.
Mar: Awarded “Top 100 Future Stars in AI-powered Innovation”.